TARDBP and frontotemporal dementia: Emerging frontiers include FTD-specific TAR DNA-binding protein 43 (TDP-43) biomarkers (Chatterjee et al., 2024) and randomized controlled trial (RCT) designs for anti-amyloid therapy evaluation (Hoilund-Carlsen et al., 2024; Logroscino et al., 2025).